UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CARDIOVASCULAR & METABOLIC

Eli Lilly and Company

E

Eli Lilly and Company

Cardiovascular & MetabolicIndianapolis, United States
Visit Website

About Eli Lilly and Company

Eli Lilly and Company is one of the oldest continuously operating pharmaceutical companies in the United States, founded in Indianapolis in 1876 by Colonel Eli Lilly, a Civil War veteran who insisted on rigorous quality standards at a time when patent medicines were largely unregulated. That founding conviction shaped a company that today ranks among the world's largest pharmaceutical enterprises by market capitalisation, listed on the New York Stock Exchange under the ticker LLY.

Diabetes & Metabolic Disease Leadership

Lilly's most consequential scientific legacy is in diabetes care. The company played a central role in the commercialisation of insulin in the early 1920s and has remained a dominant force in the category ever since. Its portfolio of insulin products and GLP-1 receptor agonist treatments has placed it at the forefront of the global obesity and metabolic disease conversation, with Mounjaro (tirzepatide) representing one of the highest-profile pharmaceutical launches of the 2020s across both type 2 diabetes and weight management indications.

Oncology & Neuroscience Portfolio

Beyond metabolic disease, Lilly operates a substantial oncology division spanning targeted therapies and immuno-oncology, alongside a long-standing neuroscience programme that has historically focused on depression, pain, and central nervous system disorders. The company has invested heavily in Alzheimer's disease research, an area where it has pursued multiple clinical programmes over several decades. Verzenio (abemaciclib) in breast cancer and Cyramza (ramucirumab) in gastric and lung malignancies anchor the oncology commercial offering.

Headquartered in Indianapolis, Indiana, Lilly operates manufacturing sites, research laboratories, and commercial offices across dozens of countries, serving patients in more than 120 markets globally. The company's R&D investment consistently ranks among the highest in the industry as a proportion of revenue, reflecting a pipeline-first culture that has defined its competitive positioning for generations.

Further information is available at lilly.com.

Similar Companies

More in Cardiovascular & Metabolic

B

Bristol Myers Squibb

Bristol Myers Squibb has built its modern identity around a singular strategic conviction: that understanding the biology of serious disease at the molecular level is the fastest route to transformative medicines. The company traces its origins to 1887, and its current form emerged from the merger of Bristol-Myers and Squibb in 1989, creating one of the world's largest research-driven biopharmaceutical companies. It is listed on the New York Stock Exchange under the ticker BMY. Oncology & Immuno-Oncology Leadership The area where BMS has most visibly reshaped clinical practice is oncology, and specifically immuno-oncology. Opdivo (nivolumab) and Yervoy (ipilimumab) are among the most widely recognised checkpoint inhibitors in global oncology, having been approved across a broad range of tumour types. The company's acquisition of Celgene in 2019, one of the largest transactions in pharmaceutical history at the time, added Revlimid and a substantial haematology portfolio, reinforcing BMS's position in multiple myeloma and other blood cancers. Cardiovascular & Immunology Pipeline Beyond oncology, BMS has longstanding expertise in cardiovascular disease, with Eliquis (apixaban), developed in partnership with Pfizer, becoming one of the most prescribed oral anticoagulants worldwide. The immunology and fibrosis franchises have grown in strategic importance, with the company investing in targeted protein degradation and cell therapy as emerging modalities. CAR T platforms, brought in through the Celgene acquisition, represent a key area of next-generation oncology development. Headquartered in Princeton, New Jersey, BMS operates across more than 40 countries, with major research campuses in the United States and Europe. The company employs tens of thousands of people globally and maintains a significant presence in clinical development, running one of the pharmaceutical industry's larger late-stage trial portfolios at any given time. Its commercial and scientific scale, combined with a focused therapeutic strategy centred on serious diseases with high unmet need, places BMS among a small number of companies that consistently shape oncology, haematology and cardiovascular treatment standards worldwide. Further information is available at bms.com.

View profile
J

Johnson & Johnson MedTech

Johnson & Johnson MedTech is one of the world's largest medical technology businesses, operating as the dedicated MedTech segment of Johnson & Johnson following the separation of its consumer health division. With roots stretching back to Johnson & Johnson's founding in 1886, the MedTech division draws on more than a century of surgical and clinical heritage to serve hospitals, surgeons, and healthcare systems across more than 100 countries. Surgical Innovation & Robotics The company is a global leader in surgical robotics and digital surgery, anchored by its OTTAVA robotic surgical system, currently in advanced development, and the established Monarch platform for bronchoscopic procedures. Its Ethicon business unit remains one of the most recognised names in sutures, surgical staplers, energy devices, and wound closure, products found in operating theatres worldwide. These portfolios sit at the intersection of hardware, software, and procedural data, reflecting the company's stated strategy of redefining surgery through intelligence and automation. Orthopaedics & Vision Johnson & Johnson MedTech holds a leading position in orthopaedics through its DePuy Synthes franchise, which covers joint reconstruction, trauma fixation, spine surgery, and sports medicine. The breadth of this portfolio makes it one of the most comprehensive orthopaedic offerings from any single manufacturer globally. Alongside surgery and orthopaedics, the company operates a substantial vision care business through its Johnson & Johnson Vision unit, producing the Acuvue range of contact lenses, among the best-selling contact lens brands in the world. Headquartered in New Brunswick, New Jersey, United States, Johnson & Johnson MedTech benefits from parent company Johnson & Johnson's listing on the New York Stock Exchange (ticker: JNJ) and its inclusion in the Dow Jones Industrial Average. Research, manufacturing, and commercial operations span multiple continents, supported by a global workforce that numbers in the tens of thousands within the MedTech segment alone. The division's focus on cardiovascular intervention, electrophysiology, neurovascular care, and general surgery continues to expand its clinical footprint beyond its established strongholds, positioning it as a broad-spectrum medical technology partner for healthcare providers at every level. Further information is available at jnjmedtech.com.

View profile
M

Medtronic

Medtronic is the world's largest dedicated medical device company, with a history stretching back to 1949 when Earl Bakken and Palmer Hermundslie founded it in a Minneapolis garage. Today headquartered in Dublin, Ireland, with operational headquarters in Fridley, Minnesota, the company employs over 90,000 people across more than 150 countries, making it a defining force in the global medical technology industry. Therapy Areas and Product Portfolio Medtronic operates across four principal business segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its cardiovascular portfolio includes pacemakers, defibrillators, heart valves, and structural heart therapies. The neuroscience segment covers deep brain stimulation systems, spinal cord stimulators, neurovascular devices, and surgical navigation platforms. The medical surgical division encompasses advanced energy tools, gastrointestinal diagnostics, and respiratory interventions. The diabetes segment produces insulin pumps and continuous glucose monitoring technology, including the widely adopted MiniMed systems. Innovation and Global Reach Listed on the New York Stock Exchange under the ticker MDT, Medtronic is a component of the S&P 500 and consistently ranks among the largest healthcare companies by market capitalisation. The company invests heavily in research and development, maintaining a substantial pipeline of next-generation devices and minimally invasive therapies. Its robotic-assisted surgical platform, the Hugo system, reflects broader ambitions in digital health and surgical robotics. Medtronic also operates one of the largest physician training and education networks in the medical device sector, supporting clinicians across specialties worldwide. The company's reach extends into emerging markets through dedicated access programmes, and it has made numerous strategic acquisitions over decades to strengthen capabilities across its core segments. Medtronic's scale, diversification across device categories, and long-standing relationships with hospital systems globally position it as an essential reference for procurement, partnership, and industry intelligence within the medical technology sector. Further information is available at medtronic.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy